ORIGINAL PAPERS

   BREAST CANCER

Clinical Development of Ixabepilone and Other Epothilones in Patients with Advanced Solid Tumors

Edgardo Rivera, Joyce Lee, Angela Davies
The Oncologist 2008; 13: 1207-1223; doi:10.1634/theoncologist.2008-0143
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses the challenges of multiple drug resistance and the data that support the use of epothilones in this setting, focusing on ixabepilone.

Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer

Daniel J. Lenihan, Francisco J. Esteva
The Oncologist 2008; 13: 1224-1234; doi:10.1634/theoncologist.2008-0112
[Abstract] [Full Text] [PDF]  

SUMMARY: This review summarizes the latest data regarding treatment-related cardiovascular adverse events in women with early breast cancer and includes highlights and considerations for assessing baseline cardiovascular risk, follow-up, and management, as well as multidisciplinary strategies to optimize patient outcomes.

Changes and Predictive and Prognostic Value of the Mitotic Index, Ki-67, Cyclin D1, and Cyclo-oxygenase-2 in 710 Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Frédérique Penault-Llorca, Catherine Abrial, Inès Raoelfils, Philippe Chollet, Anne Cayre, Marie-Ange Mouret-Reynier, Emilie Thivat, Florence Mishellany, Pierre Gimbergues, Xavier Durando
The Oncologist 2008; 13: 1235-1245; doi:10.1634/theoncologist.2008-0073
[Abstract] [Full Text] [PDF]  

SUMMARY: The authors evaluated the mitotic index of the Scarff–Bloom–Richardson grade, Ki-67, cyclin D1, and cyclo-oxygenase before and after neoadjuvant chemotherapy in breast cancer patients to assess their predictive and prognostic value.

Cancer and Immune Response: Old and New Evidence for Future Challenges

Luis de la Cruz-Merino, Enrique Grande-Pulido, Ana Albero-Tamarit, Manuel Eduardo Codes-Manuel de Villena
The Oncologist 2008; 13: 1246-1254; doi:10.1634/theoncologist.2008-0166
[Abstract] [Full Text] [PDF]  

SUMMARY: This manuscript reviews some recent studies and new concepts that assess the efficacy of the natural antitumor immune response in cancer and the strategies developed to stimulate it from a clinical point of view.

Carcinoid Tumors

Scott N. Pinchot, Kyle Holen, Rebecca S. Sippel, Herbert Chen
The Oncologist 2008; 13: 1255-1269; doi:10.1634/theoncologist.2008-0207
[Abstract] [Full Text] [PDF]  

SUMMARY: This paper reviews the classification, diagnosis, and treatment of carcinoid tumors.

High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical Practice

Daniele Santini, Fotios Loupakis, Bruno Vincenzi, Irene Floriani, Irene Stasi, Emanuele Canestrari, Eliana Rulli, Paolo Enrico Maltese, Francesca Andreoni, Gianluca Masi, Francesco Graziano, Giacomo Giulio Baldi, Lisa Salvatore, Antonio Russo, Giuseppe Perrone, Maria Rosa Tommasino, Mauro Magnani, Alfredo Falcone, Giuseppe Tonini, Annamaria Ruzzo
The Oncologist 2008; 13: 1270-1275; doi:10.1634/theoncologist.2008-0181
[Abstract] [Full Text] [PDF]  

SUMMARY: This study evaluated concordance in terms of KRAS status between colorectal cancer primaries and related metastases. The results show concordance between the detection of KRAS mutations in primary and metastatic tumors and suggest that this assessment could be used to predict response to targeted therapies such as cetuximab and panitumumab.

Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR) Mutations with the Classical Mutation Pattern

Shang-Gin Wu, Yih-Leong Chang, Ya-Chieh Hsu, Jenn-Yu Wu, Chih-Hsin Yang, Chong-Jen Yu, Meng-Feng Tsai, Jin-Yuan Shih, Pan-Chyr Yang
The Oncologist 2008; 13: 1276-1284; doi:10.1634/theoncologist.2008-0093
[Abstract] [Full Text] [PDF]  

SUMMARY: This study investigated the clinical characteristics and response to gefitinib of lung adenocarcinoma patients with complex EGFR mutations. Patients with complex EGFR mutations with the classical mutation pattern had the same response rate, progression-free survival duration, and overall survival time as those with single classical mutations.

Clinical Patterns and Biological Correlates of Cognitive Dysfunction Associated with Cancer Therapy

Jörg Dietrich, Michelle Monje, Jeffrey Wefel, Christina Meyers
The Oncologist 2008; 13: 1285-1295; doi:10.1634/theoncologist.2008-0130
[Abstract] [Full Text] [PDF]  

SUMMARY: This review summarizes the clinical spectrum of cancer treatment–associated neurotoxicity with special emphasis on cognitive dysfunction. Recent developments in the understanding of the cellular mechanisms underlying cancer therapy–associated neurotoxicity are highlighted.

Persistence, Up to 18 Months of Follow-Up, of Epirubicin-Induced Myocardial Dysfunction Detected Early by Serial Tissue Doppler Echocardiography: Correlation with Inflammatory and Oxidative Stress Markers

Giovanni Mantovani, Clelia Madeddu, Christian Cadeddu, Mariele Dessì, Alessandra Piras, Elena Massa, Roberto Serpe, Giorgia Antoni, Giuseppe Mercuro
The Oncologist 2008; 13: 1296-1305; doi:10.1634/theoncologist.2008-0151
[Abstract] [Full Text] [PDF]  

SUMMARY: This study used TDI to detect early preclinical changes predictive of heart failure risk in epirubicin-treated cancer patients and correlated those findings with levels of inflammatory and oxidative stress markers. The study found subtle cardiac abnormalities at a 200 mg/m² cumulative epirubicin dose that persisted through 18 months of follow-up. These abnormalities were associated with high levels of inflammatory and oxidative stress markers.

A Public Health Approach to Winning the War Against Cancer

Thomas R. Frieden, Julie E. Myers, Marian S. Krauskopf, Thomas A. Farley
The Oncologist 2008; 13: 1306-1313; doi:10.1634/theoncologist.2008-0157
[Abstract] [Full Text] [PDF]  

SUMMARY: This article describes a prevention strategy for the United States to help win the war on cancer. Prevention can be achieved by reducing exposure to cancer-promoting agents, particularly tobacco but also alcohol and caloric imbalance; vaccination against specific virus-associated cancers; and early detection and treatment. These require more funding and a greater emphasis on public health programs and public policy.

Osteonecrosis of the Jaw and the Use of Antiangiogenic Agents: Just an Association?

Jeanny B. Aragon-Ching, William L. Dahut
The Oncologist 2008; 13: 1314; doi:10.1634/theoncologist.2008-0206
[Full Text] [PDF]  

In Reply

Cherry L. Estilo, Catherine Van Poznak, Joseph M. Huryn
The Oncologist 2008; 13: 1315; doi:10.1634/theoncologist.2008-0228
[Full Text] [PDF]  

Acknowledgments

The Oncologist 2008; 13: 1316-1317
[Full Text] [PDF]  

Author Index

The Oncologist 2008; 13: 1318-1321
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.